615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Commercially Available Therapy, excluding Transplantation II
Watch Session
632 Phase 3b Study Assessing the Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed, FLT3-Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for 7+3 or 5+2 ChemotherapyJorge Sierra, Pau Montesinos, Xavier Thomas, et al.
Timothy S. Pardee, Kristin M. Pladna, Susan Lyerly, et al.
Jorge Labrador, David Martínez-Cuadrón, Adolfo de la Fuente, et al.
et count <20 x109/L and estimated glomerular filtrate rate ≥ 45 mL/min/1.73m2 could benefit from AZA in terms of OS.
Jeffrey E. Lancet, Geoffrey L Uy, Laura F. Newell, et al.
Eytan M. Stein, Ying Huang, Uma Borate, et al.
Abhishek Maiti, Courtney D. DiNardo, Tapan M. Kadia, et al.